• Home
  • NEW DAY MEDICINE
  • 6 (44) 2022
  • 18 — 6 (44) 2022 — Kholikova N.A., Mamasoliev N.S., Usmonov B.U., FUTURE STRATEGIES IN THE FIELD OF PREVENTION OF BRONCHIAL ASTHMA

18 — 6 (44) 2022 — Kholikova N.A., Mamasoliev N.S., Usmonov B.U., FUTURE STRATEGIES IN THE FIELD OF PREVENTION OF BRONCHIAL ASTHMA

FUTURE STRATEGIES IN THE FIELD OF PREVENTION OF BRONCHIAL ASTHMA

Kholikova N.A., Andijan State Medical Institute and RRCEM AB

Mamasoliev N.S., Andijan State Medical Institute and RRCEM AB

Usmonov B.U., Andijan State Medical Institute and RRCEM AB

Resume

The authors examined patients in the city of Andijan, which is fully represented by the climatic conditions of the Ferghana Valley. The work will be carried out as part of an analytical retrospective 20-year epidemiological study. Written consent was obtained for the study. The departments of the Andijan branch of the Republican Scientific Center for Emergency Medicine (AF RNCEMP) were taken as an object. With the help of a special questionnaire for the identification of chronic non-communicable diseases and their risk factors (WHO, 2009), the medical history of patients with bronchial asthma for the period 2000-2020 was analyzed and studied. As part of a 20-year monitoring analysis, treatment programs are studied and evaluated using a Pharmacoepidemiological Questionnaire. The questionnaire consisted of 10 sections and 165 questions, which allows a patient with bronchial asthma to form a complete diagnosis (primary, complication, sibling disease, competitive disease, underlying disease). The questionnaire fully reflects the risk factors and the clinical course of the disease, the sensitivity and specificity of which have been confirmed at the WHO level and are recommended for epidemiological studies. This method of examination and analysis has been tested abroad (WHO, 2000-2019; Scientific Center for Preventive Medicine of the Russian Federation, 2008-2020). These two questionnaires are completed for each patient. The authors will analyze about 50,000 patients, and this large-scale and promising 20-year epidemiological monitoring will have great scientific and practical potential, making unprecedented and unambiguously substantiated scientific conclusions in Uzbekistan

Keywords: Bronchial asthma, prevention, screening strategies

First page

104

Last page

111

For citation: Kholikova N.A., Mamasoliev N.S., Usmonov B.U., FUTURE STRATEGIES IN THE FIELD OF PREVENTION OF BRONCHIAL ASTHMA //New Day in Medicine 6(44)2022 104-111 https://clck.bar/Lb6b4e

LIST OF REFERENCES:

  1. Бронхиальная астма. Клинические рекомендации // МОО Российское респираторное общество, Российское респираторное общество, Российская ассоциация аллергологов и клинических иммунологов. – 2018. – С. 88 – 90.
  2. Дынева М. Е., Курбачева О.М., Савлевич Е.Л. Бронхиальная астма в сочетании с хроническим полипозным риносинуситом: эпидемиология, распространенность и особенности их взаимоотношения //Российский аллергологический журнал. – 2018; 15 (1-1):16-25.
  3. Коныщева А.Ю., В.Б. Гервазиева, Осилова Г. Л., Оспельникова Т.П., Феномен аутореактивности в потогенезе сочетания бронхиальной астмы и хронической обструктивной болезни легких //Пульмонология. – 2021. – Том31. – №1. – С. 46-51.
  4. Курбачева О.М., Дынева М.Е., Шиловский И.П., Савлевич Е.Л и др. Особенности молекулярных механизмов потогенеза бронхиальной астмы в сочетании с полипозным риносинуситом // Пульмонология. – 2021. – Том 31. – №1. – С. 7 – 17.
  5. Курбачева О.М., Павлова К.С. Фенотипы и эндотипы бронхиальной астмы: от потогенеза и клинической картины к выбору терапии // Россий аллергологический журнал. – 2003; (1): 15 -24.
  6. Национальная программа “Бранхиальнаяастма у детей стратегия лечения и профилактика”, IV издание. – М. – 2012. – С 182.
  7. Савлевич Е.Л., Дынева М.Е., Гаганов Л.Е., и др. Лечебно – диагностический алгоритмы при разных фенотипах полипозного риносинусита // Российских аллергических журнал. – 2019: 16(2):56-60.
  8. Савлевич Е.Л., Гаганов Л.Е., Егоров В.И. ва б.қ. Сравнительное пилотное исследования эндотипов хронического полипозного риносинусита у пациентов, проживающих в разных географических регионах Российской Федерации // Иммунология. – 2018. – 39(4): 208-213.
  9. Чучалин А.Г., Авдеев С.Н., Айсинов З.Р. и др. Российское респираторное общество Федеральные клинические рекомендации по диагностике и лечению хронической обструктивной болезни легких // Пульмонология. – 2014. – №3, – С.15 -54.
  10. Шиловский И.П., Дынева М.Е., Курбачева О.М. ва б.ы. Роль интерлейкине – 37 в патогенеза аллергических заболеваний // Асta natural – 2019:11 (4): 34 – 64.
  11. Agusti. A., Calverley P.M., Celli B. et al. Charactericterisation of COPD heterogeneity is the ECLIPSE cohort //Respir Res: 2010; 11(1): 122.
  12. Asher M,J., Montefort S., Biorkster B. et al. woridwide time trends in the prevalence of symtoms of asthma, allergic rhihocohjunctivitis, and eczema in childhood. ISAAC PLASES One and Three repeat multicountry cross sectional surveys // Lancet – 2006; 368 (9537): 733-743.
  13. Bateman E.D., Reddel U.K., Eriksson G et al. Overali asthma control: The rebationship between cyrrent control and futeru risk // J. Allergy Clih. Immunal – 20103125 (3): 600-608 ст. DOI:10. 1016/j. jaci.2009.11.033.
  14. Bel EH, Wehrel SE, Thompson P.J. et al. SIRIUS Investigators. Oral glucocorticoid sparing effect of mepolizumab in eosinophilic asthma // N Ehge S Med. – 2014; 371 (13): 1189-1197
  15. Buhl R., Heaney I.G., Loefroth E. et al. One-year follow on of  asthmatic patients newly initiated on treatment with medidium of hish-dose inhaled corticosteroid long-acting br-agonist in Ukprimary care seltinge // Respir. Med. 2020; 162-105859.
  16. Chaban M.R., Walsh E. M., Woodwonh B.A. Epidemiology and differential diagnosis of hasal polyps // Am. J. Phinol. Allergy – 2013; 27 (6): 673 – 478
  17. Chuchalih A.C., Khaltaev N., Antonov N. S., et al. Chrohis respiratory diseases and risk factors in 12 regions of Russian federation // Int. J. Chroh. Obstruk. Pulmol Dis. 2014; -9 (1): 963 – 974
  18. Cosio B. C., Soriano J. B., Lopez – Compos J.I et al. Defining the asthma – СopD overlop syndrome in a COPD cohort // Chest – 2016; 149 (1): 45-52
  19. Fokkens W.J., Lund V.J., Mullol J. et al. European position paper on rhinosinusi tis and hasal polyps 2012. // Rhinology. – 2012; so (suppl. 23): 1 – 298.
  20. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease study 2016 // Lancet. – 2017;390(10100):1211-1259. DOI:10.1016//S0140-6736(17)32154-2.
  21. Generoso A., Oppenheimer J. Asthma/obstructive pulmonary disease overlap: update on definition, biomarkers, and therapeutic //Curr. Opin. Allergy Clin. Immunol. – 2020; 20(1):43-47.
  22. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease study 2019 // Lancet. 2020; 396(10258):1204-22 https.//www.thelancet.com/gbd/summaries.
  23. Global Health Estimates 2016: Deaths by Cause, Age, sex, by Country and by Region, 2000-2016. Geneva:Worid Health Organization; 2018.
  24. Global Inifiative for Asthma. Global Strategy for Asthma Management and Prevention 2016
  25. Global Initiative for Asthma 2019 GINA Report. Global strategy for Asthma Management and Prevention. Avaitlable at: https://ginaasthma.org/reports/2019.gina report. Global-strategy for – asthma – management – and – prevention/ [Accewed:May 11.2020].
  26. Global initiative for Asyhma. 2020 GINA Report, Global strategy for Asthma Management and Prevention. Available at: https://ginaasthma.org/gina-reports/ [Accessed:July 17. 2020].
  27. Global strategy for Asthma Management and Prevention. Revised 2017 //www.ginasthma.com.
  28. Global, regional, and national deaths, prevalence, disability adjusied life years, and years lived with disability for chronic obstructive pulmonary diseasc and asthma, 1990-2015; a systematic analysis for the Global Burden of Disease study 2015// Lancet Respir. Med. – 2017; 5(9): 691-706.
  29. Global, regional, and national deaths, prevalence, disability adjusied life years, and years lived with disability for chronic obstructive pulmonary diseasc and asthma, 1990-2015; a systematic analysis for the Global Burden of Disease study 2015// Lancet Respir. Med. – 2017; 5(9): 691-706.
  30. Inoue H., Nagase T., Morita S. et al. Prevalence and characteristics of asthma – COPD overtap syndrome identified by a stepwise approach // Int.J. Chron. Obstruct.Pulmon. Dis.2017;12:1803-1810. DOI:10.2147/COLD S 133859.
  31. Kim D.W., Cho S.H. Emerging endotypes of chronic rhinosinusitis and its application to precision medicine. Allergy //Asthma immunol. Res. – 2017;9(4):299-306.
  32. Moore W, Meyers D., Wenzel S., Teague G., Li H. et al. Identification of Asthma Phenotypes Using Cluster Analysis in the Severe Asthma Research Program // Am J Respir Crit Care Med. – 2010 Feb 15;181(4):315-323.
  33. Ortega HG, LiuMC, Pavord ID et al. Mepolizumab treatment in patients with severe eosinophilic asthma // N Enge J Med. – 2014 – 371: 1198-1207.
  34. Putcha N., Wise R.A. Asthma – chronic obstructive pulmonary disease overlap syndrome: nothing new under the sun// Immunol. Allergy Clin. North. Am. – 2016; 36(3):515-528.
  35. Serrano F., Neukirch F., Pribil C. et al. Nasal polyposis in France: impact onn sleep and guality of life // J. Laryngol.Otol. – 2005.-119(7):543-549.
  36. Soler I.M., Mace S.C., Litvack J.R., Smith T.L. Chromic rhinosinusitis, race, and ethnicity //Am. J. Rhinol. Allergy – 2012:26:110-116.
  37. Stanford R.H., Gilsenan A.W., Ziemiecki R et al. Predictors of uncontroiled asthma in adult and pediatric patients: Analysis of the Asthma Control Characteristics and Prevalence Survey Studies (ACCFSS) // J. Asthma. – 2010;47(3):257-262.
  38. Stevens W.W., Peters A.T., Hirsch A.G. et al Clinical chracteristics of patients with chronic rhinosinusitis with nasal polyps, asthma, and aspirin-exacerbated respiratory disease // J. Allergy Clin. Immunol. Pract. – 2017; 5(4):2061-1071.e3.
  39. Tao L, Shi B., Shi G, Wan H. Efficacy of sublingual immunotherapy for allergic asthma: retrospective meta-analysis of randomized, double-blind and placebo controlled trials //Clin Respir J. – 2014:8:192-205
  40. Virchow JC, Backer V, Runa P. et al. Efficacy of a hause dust mite sublingualallergen immunotherapy tablet in adults with allergic asthma: A randomized clinical trial // Jama. 2016:315:1715-25.
  41. Zaurbek R. Aisanov, Sergey N. Avdeev, Andrey S. Belevskiy et al. the position of the fixed combination of indaceterol, glycopyrronium, and mometasone furoate in the management of bronchial asthma. The Report of Expert Panel of Russian Respiratory Society // Pulmonologya – 2021; 31(1):66-74.

file

download